MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ
5.46
+0.14
+2.63%
Closed 13:00 11/25 EST
OPEN
5.35
PREV CLOSE
5.32
HIGH
5.46
LOW
5.35
VOLUME
620
TURNOVER
3.20K
52 WEEK HIGH
25.80
52 WEEK LOW
2.423
MARKET CAP
51.40M
P/E (TTM)
-1.0113
1D
5D
1M
3M
1Y
5Y
--Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating
--Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating
MT Newswires · 11/09 09:27
Recap: Avalo Therapeutics Q3 Earnings
Benzinga · 11/07 14:36
BRIEF-Avalo Reports Third Quarter Financial Results
Reuters · 11/07 14:36
Avalo Therapeutics GAAP EPS of $0.34 beats by $1.04, revenue of $14.95M
Seekingalpha · 11/07 13:22
BRIEF-Avalo Sells Economic Rights To Certain Assets For $5 Million
Reuters · 11/07 12:51
Avalo Therapeutics Q3 EPS $0.34 Up From $(2.08) YoY, Sales $14.95M Up From $1.35M YoY
Benzinga · 11/07 12:36
-- Earnings Flash (AVTX) AVALO THERAPEUTICS Posts Q3 Revenue $14.9M
-- Earnings Flash (AVTX) AVALO THERAPEUTICS Posts Q3 Revenue $14.9M
MT Newswires · 11/07 07:33
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers
Benzinga · 09/08 09:26
More
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage precision medicine company. The Company discovers, develops, and commercializes therapeutics for patients with unmet clinical needs in immunology and rare genetic diseases. Its clinical-stage pipeline includes AVTX-002, AVTX-007, and AVTX-800 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, moderate to severe inflammatory bowel disease, and COVID-19 acute respiratory distress syndromes. AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA). Its AVTX-800 programs include AVTX-801 and AVTX-803, AVTX-802, AVTX-008, and AVTX-006. VTX-801 and AVTX-803 are monosaccharide therapies for the treatment of congenital disorders of glycosylation (CDGs). AVTX-006 is a dual mTORc1/c2 small molecule inhibitor for the treatment of complex lymphatic malformations.

Webull offers kinds of Avalo Therapeutics Inc stock information, including NASDAQ:AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.